Neurogene Inc. Faces Uncertainty with NGN-101 Program Amid FDA Challenges and Strategic Hurdles
Neurogene Inc. (NGNE) has disclosed a new risk, in the Corporate Activity and Growth category.Don't Miss out on Research Tools:Discover the ...
BioSpace3h
RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More
Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.
Promising Outlook for Neurogene’s Low-Dose NGN-401 Program in Rett Syndrome
Keith Tapper CFA, an analyst from BMO Capital, maintained the Buy rating on Neurogene (NGNE – Research Report). The associated price target ...
BioPharma Dive23h
Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer
The agency turned back Astellas’ attempt to update its drug Izervay’s labeling. Elsewhere, former NCI director Ned Sharpless ...